| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
The molecular targets of 7-Hydroxyisoflavone include viral targets involved in Enterovirus 71 replication, as demonstrated by its antiviral activity. As a phytoestrogen, it interacts with estrogen receptors, making it a valuable molecule for hormone-related research. The compound may also have other targets involved in cancer, cardiovascular disease, and neurodegenerative disorders.
|
|---|---|
| ln Vitro |
7-Hydroxyisoflavone exhibits strong antiviral activity against three different EV71 strains in vitro. The 50% inhibitory concentration range was between 3.25 and 4.92 μM by cytopathic effect assay. This antiviral activity has not been reported for the structurally similar comparator daidzein. The compound's phytoestrogenic properties have also been noted.
|
| ln Vivo |
Specific in vivo activity data for 7-Hydroxyisoflavone are not available in the consulted sources. As a phytoestrogen, it may have effects on hormone-related conditions in vivo. Its antiviral activity against EV71 has been demonstrated in vitro, but in vivo efficacy has not been reported. Further studies are needed to evaluate its potential as an antiviral or phytoestrogen agent.
|
| Enzyme Assay |
Typical in vitro assays for 7-Hydroxyisoflavone include cytopathic effect (CPE) assays for antiviral activity. Cells (e.g., Vero cells) are infected with EV71 and treated with the compound at various concentrations. After incubation, the extent of cytopathic effect is assessed microscopically or by MTT assay. The IC₅₀ is calculated from dose-response curves. For estrogen receptor binding, competitive binding assays are performed using radiolabeled estradiol and estrogen receptor preparations.
|
| Cell Assay |
Cellular assays for 7-Hydroxyisoflavone typically involve treating cells (e.g., Vero cells for antiviral studies, or breast cancer cells for estrogen receptor studies) with the compound at concentrations ranging from 0.1-100 µM. For antiviral activity, cells are infected with EV71 and treated with the compound, and viral replication is assessed by CPE reduction or viral RNA quantification. For estrogen receptor activity, reporter gene assays are used to measure estrogen-responsive element activation.
|
| Animal Protocol |
In vivo animal experiments for 7-Hydroxyisoflavone are not detailed in the available literature. For antiviral studies, typical animal models include EV71-infected mice. The compound would be administered orally or intraperitoneally, and viral load, clinical signs, and survival would be assessed. For phytoestrogen studies, ovariectomized rodent models are used. However, such studies have not been reported for this specific compound.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
7-Hydroxyisoflavones are known human metabolites of isoflavones. Pharmacokinetic data for 7-Hydroxyisoflavone are limited. As a small isoflavone with a molecular weight of 238.24 g/mol, it would be expected to have reasonable oral bioavailability. Isoflavones are known to be absorbed and metabolized by conjugation reactions. However, detailed PK parameters are not available in the consulted sources. |
| Toxicity/Toxicokinetics |
Toxicological data for 7-Hydroxyisoflavone are limited. As a natural isoflavone and phytoestrogen, it is generally considered to have low toxicity at dietary levels. However, high doses may have hormonal effects. Comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
7-Hydroxyisoflavones are the simplest members of the 7-hydroxyisoflavone class, namely isoflavones with a hydroxyl substituent at the 7-position. It is an EC 1.14.14.14 (aromatase) inhibitor and metabolite. It is the conjugate acid of 7-hydroxyisoflavone (1-). 7-Hydroxyisoflavones have been reported in Echinops echinatus and Muntingia calabura, and relevant data are available.
7-Hydroxyisoflavone is a natural isoflavone compound with antiviral activity against Enterovirus 71 (IC₅₀: 3.25-4.92 μM). As a phytoestrogen, it interacts with estrogen receptors and is studied for hormone-related cancers, cardiovascular diseases, and neurodegenerative disorders. The compound is a research chemical and is not approved for any clinical indication. |
| Molecular Formula |
C15H10O3
|
|---|---|
| Molecular Weight |
238.24
|
| Exact Mass |
238.062
|
| CAS # |
13057-72-2
|
| PubChem CID |
5376891
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
450.1±45.0 °C at 760 mmHg
|
| Melting Point |
214.0 to 218.0 °C
|
| Flash Point |
176.3±22.2 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.666
|
| LogP |
3.02
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
355
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WMKOZARWBMFKAS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O3/c16-11-6-7-12-14(8-11)18-9-13(15(12)17)10-4-2-1-3-5-10/h1-9,16H
|
| Chemical Name |
7-hydroxy-3-phenylchromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1974 mL | 20.9872 mL | 41.9745 mL | |
| 5 mM | 0.8395 mL | 4.1974 mL | 8.3949 mL | |
| 10 mM | 0.4197 mL | 2.0987 mL | 4.1974 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
